A retrospective study was performed on 1296 female breast cancer patients with histologically confirmed invasive ductal breast carcinoma (IDC) from Fudan University Shanghai Cancer Center (FUSCC) between January 1, 2007 and December 31, 2009. Patients had operable tumors measured by MRI, ultrasound or mammography were enrolled, and those with inoperable lesions were excluded. All the enrolled patients underwent surgical treatment at FUSCC. Surgical resection of the tumor was performed two days after the imaging measurement. Follow-up was completed on September 1, 2013. The median length of follow-up was 44 months (range from 2 to 75 months). Our definition of disease-free survival (DFS) events included: the first recurrence of disease at a local, regional, or distant site; the diagnosis of contralateral breast cancer; and death from any causes. Overall survival (OS) was calculated from the date of diagnosis to the date of death or last follow-up. Patients without events or death were censored at the last follow-up. One hundred and eighty patients had DFS events and 134 had died at the end of follow-up. Molecular subtypes of breast cancer according to immunohistochemical profile were categorized as follow: luminal A = (ER or PR) +, HER2− and Ki67<14%; luminal B = (ER or PR)+and (HER2+ or Ki67≥14%); HER2+ = ER-, PR- and HER2+; and basal-like = ER-, PR-, HER2− and (CK5/6+ or EGFR+) [8] (link), [9] (link). Staining and interpretation of ER, PR, HER2, Ki-67, EGFR, and CK5/6 have been previously described [10] (link). Our study was approved by the independent ethical committee/institutional review board of FUSCC (Shanghai Cancer Center Ethical Committee). All patients gave their written informed consent before inclusion in this study.
Free full text: Click here
